Physician profile
Gary K Pang
NPI 1851486310
$18,941.66
in general payments reported to CMS, 2019-2025
37 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what 77% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,806 · 2020: $2,817 · 2021: $1,347 · 2022: $5,830 · 2023: $2,943 · 2024: $1,666 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,109 · Education: $33.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,108.68 |
| Education | $33.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $4,273.82 | 2019-2024 | Senza |
| Spinal Simplicity, LLC | $1,961.95 | 2022-2024 | Ha Minuteman G3-R |
| Medtronic, INC. | $1,670.38 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Osteocool Rf Ablation System |
| Abbott Laboratories | $1,665.85 | 2019-2025 | Proclaim, Eterna |
| Medtronic USA, INC. | $1,365.50 | 2019-2020 | |
| Painteq LLC | $1,081.15 | 2021-2024 | Painteq |
| Boston Scientific Corporation | $989.22 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Mml US, INC. | $961.39 | 2022 | |
| Si-Bone, INC. | $872.25 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $561.14 | 2020-2025 | Xtampza, Belbuca |
| Pfizer INC. | $509.74 | 2019-2021 | |
| Spr Therapeutics, INC | $509.14 | 2022-2023 | Sprint Pns System |
| Globus Medical, INC. | $398.62 | 2025 | Senza, Vyrsa V1 |
| Saluda Medical Americas, INC. | $333.85 | 2023-2025 | Evoke, Evoke Scs |
| International Rehabilitative Sciences, INC | $260.06 | 2021-2025 | Rs-4i Plus With Intersperse, Rs 4i Plus Sequential Stimulator |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $238.42 | 2023 | Intracept |
| Scilex Pharmaceuticals INC. | $227.62 | 2019-2024 | Ztlido |
| Abbvie INC. | $196.98 | 2022 | |
| Biotronik Nro, INC. | $151.57 | 2025 | Prospera |
| Curonix LLC | $140.22 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biodelivery Sciences International, INC. | $138.85 | 2019-2021 | |
| Daiichi Sankyo INC. | $53.87 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.16 | 2022 | |
| Lundbeck LLC | $39.09 | 2024-2025 | Vyepti |
| Avanos Medical | $36.27 | 2020 | |
| Stimwave Technologies Incorporated | $36.26 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $34.62 | 2024 | |
| Averitas Pharma INC. | $30.99 | 2025 | Qutenza |
| Kaleo, INC. | $28.72 | 2019 | |
| Indivior INC. | $28.34 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $24.44 | 2024 | Levorphanol Tartrate |
| Astrazeneca Pharmaceuticals LP | $16.71 | 2019 | |
| Forte Bio-Pharma LLC | $16.00 | 2024 | Prolate, Nalocet |
| Nalu Medical, INC. | $15.72 | 2023 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $15.52 | 2023 | Mild Device Kit |
| Electronic Waveform Lab, INC. | $15.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.